辅助治疗对韩国WHO II级胶质瘤患者生存的影响:KNOG 15-02与KROG 16-04组间研究
该研究回顾性分析了韩国14家机构2000至2010年间555例成人WHO II级低级别胶质瘤患者的治疗结局与预后因素,中位随访83.4个月,5年无进展生存率和总生存率分别为52.2%和83.0%。全切除与更好的无进展生存和总生存相关,辅助化疗与无进展生存改善相关,辅助放疗未改善无进展生存且与更差的总生存相关;倾向评分匹配后匹配放疗组无进展生存有改善趋势,总生存无显著差异。
要点
- 全切除与更好的无进展生存和总生存相关,是改善低级别胶质瘤患者生存的重要因素。
- 辅助化疗与无进展生存改善相关。
- 辅助放疗未改善无进展生存,且与更差的总生存相关;倾向评分匹配后匹配放疗组无进展生存有改善趋势,总生存无显著差异。
核心结论
- 实现全切除对改善低级别胶质瘤患者生存重要;辅助化疗可能改善无进展生存,但辅助放疗未改善生存结局;倾向评分匹配后观察到辅助放疗对无进展生存的潜在影响。
研究设计与样本
- 回顾性分析韩国14家机构2000至2010年间555例成人WHO II级低级别胶质瘤患者的病历资料,采用倾向评分匹配校正辅助治疗组间患者/肿瘤特征不平衡。
主要发现
- 中位随访83.4个月,5年无进展生存率为52.2%,5年总生存率为83.0%。
- 男性、年龄较大、体力状态较差、多脑叶受累和星形细胞瘤组织学与更差的生存相关。
- 全切除与更好的无进展生存和总生存相关,辅助化疗与无进展生存改善相关。
- 辅助放疗未改善无进展生存,反而与更差的总生存相关;放疗组患者/肿瘤特征较非放疗组更差。
- 倾向评分匹配后,匹配放疗组无进展生存有改善趋势,总生存与匹配非放疗组无显著差异。
关键数值与推荐
- 组织学构成:星形细胞瘤37.8%,少突星形细胞瘤15.3%,少突胶质细胞瘤46.8%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Optimal treatment strategies for low-grade glioma (LGG) remain controversial. We analyzed treatment outcomes and evaluated prognostic factors of adult LGG patients in Korea. METHODS: We reviewed the medical records of 555 patients diagnosed with WHO grade II LGG (astrocytoma 37.8%, oligoastrocytoma 15.3%, and oligodendroglioma 46.8%) at 14 institutions between 2000 and 2010. Primary and secondary endpoints were progression-free survival (PFS) and overall survival (OS). Propensity-score matching (PSM) analyses were performed to correct imbalances in patient/tumor characteristics among adjuvant treatment groups. RESULTS: The median follow-up time was 83.4 months, and the 5-year PFS and OS rates were 52.2% and 83.0%, respectively. Male, older age, poorer performance status, multiple lobe involvement, and astrocytoma histology were associated with poorer survival. Among the treatment factors, gross total resection (GTR) was associated with better PFS and OS, and adjuvant chemotherapy with improved PFS. Interestingly, adjuvant radiotherapy (RT) did not improve PFS; rather, it was related with poorer OS. Regarding patient/tumor characteristics, the RT group had poorer characteristics than the non-RT group. After PSM, we detected a tendency for improved PFS in the matched RT group, and no significant difference in OS compared with the matched non-RT group. CONCLUSIONS: The achievement of GTR is important to improve survival in LGG patients. Adjuvant chemotherapy may enhance PFS, but adjuvant RT did not improve survival outcomes. After PSM, we observed potential impacts of adjuvant RT on PFS. Our results may reflect real-world practice and consequently may help to optimize treatment strategies for LGG.
引用
- Koo T, Lim DH, Seol HJ, et al. Impact of adjuvant treatments on survival in Korean patients with WHO grade II gliomas: KNOG 15-02 and KROG 16-04 intergroup study. J Neurooncol. 2018. PMID: 30097825. doi:10.1007/s11060-018-2972-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。